Investigating FP002 for advanced solid tumors

A Phase 1 Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Activity of FP002 in Subjects With Advanced Malignancies

This study is testing a new treatment called FP002 to see if it is safe and effective for people with advanced solid tumors.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Guangdong Fapon Biopharma Inc. (Industry-sponsored)
• Drugs / interventions: chemotherapy, immunotherapy
• Locations: 3 sites (Xiamen, Fujian and 2 other locations)
• Trial ID: NCT05982080 on ClinicalTrials.gov

What this trial studies

This phase 1 study aims to evaluate the safety and tolerability of FP002 as a monotherapy in patients with advanced solid tumors. The study will assess the pharmacokinetic and pharmacodynamic profiles, immunogenicity, and preliminary anti-tumor activity of FP002. Participants will receive FP002 injections, and the study will determine the recommended dose for further expansion based on the findings.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with advanced solid tumors that have not responded to standard treatments.

Not a fit: Patients who have received prior anti-CD47 or anti-SIRPα agents may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for patients with advanced solid tumors who have limited or no standard treatment alternatives.

How similar studies have performed: While this approach is novel, similar studies targeting advanced malignancies have shown promise in the past.

Eligibility criteria

Inclusion Criteria:

1. Signed informed consent form (ICF) and was able to comply with the protocol.
2. Male or female subjects ≥ 18 years of age on the day of ICF signing.
3. A life expectancy of \> 3 months.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
5. Adequate organ and bone marrow function confirmed at screening and within 7 days before the first dose of study treatment.
6. Subjects with histologically or cytological confirmed malignancy diagnosis.
7. Documented advanced solid tumors, defined as patients have no standard treatment or who have failed/are intolerant to standard treatment according to the investigator's judgment.
8. Documented with at least 1 measurable lesion as assessed by RECIST 1.1.
9. Toxicity from prior anti-tumor treatment has resolved to ≤ Grade 1 as defined by NCI CTCAE v5.0.

Exclusion Criteria:

1. Subjects who have received other anti-CD47 or anti- SIRPα agents.
2. Prior organ or tissue allograft except for hematopoietic stem cell transplantation.
3. Treatment with investigational therapy within 4 weeks prior to initiation of study drug.
4. Severe infection requiring hospitalization or IV antibiotics, antivirals or antifungals within 14 days prior to enrollment.
5. Subjects who have received chemotherapy within 4 weeks or 5 half-lives (whichever is shorter) before the first dose (within 6 weeks before the first dose of mitomycin or nitrosoureas) or received immunotherapy, radical radiotherapy or major surgery within 4 weeks or palliative radiotherapy within 2 weeks.
6. Subjects who have experienced active autoimmune disease requiring systemic therapy within the past 2 years.
7. A positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by a certified nucleic acid test within the last 30 days before the first dose of study treatment.
8. Cardiovascular dysfunction or clinically significant cardiac disease.
9. Active infection with hepatitis C.
10. Receipt of a live vaccine within 30 days prior to the first dose of study treatment.
11. Known hypersensitivity to either the drug substances or inactive ingredient of FP002.
12. Known human immunodeficiency virus (HIV) positive.
13. A history of other malignancies other than effectively treated basal cell carcinoma of skin, squamous cell carcinoma of skin, or effectively resected carcinoma in situ of the cervix.
14. Known inherited or acquired bleeding disorders.
15. Any other medical, family, social or mental conditions that the investigator considers unsuitable for participation in the study.
16. Daily requirement for corticosteroids (≥10 mg/kg) within 2 weeks prior to Day 1 of Cycle 1.
17. Women who are lactating or pregnant as confirmed by pregnancy test within 7 days before the first dose of study treatment. Unwilling to use adequate contraceptive methods during the study and for at least 7 months after the last dose of study treatment.
18. Presence of active brain metastases

Where this trial is running

Xiamen, Fujian and 2 other locations

• The First Affiliated Hospital of Xiamen University — Xiamen, Fujian, China (Not_yet_recruiting)
• Shangdong Cancer Hospital & Institute — Jinan, Shangdong, China (Recruiting)
• Linyi Cancer Hospital — Linyi, Shangdong, China (Not_yet_recruiting)

Study contacts

• Principal investigator: Yuping Sun, MD — Shangdong Cancer Hospital & Institute
• Study coordinator: Arron Wang

Conditions Advanced Solid Tumor